NeoGenomics Aims to Remap Cancer Diagnostics with PanTracer Pro Launch

FORT MYERS, Fla. – February 12, 2026 – In a move aimed at cutting through the complexities of modern cancer care, diagnostics firm NeoGenomics has launched PanTracer Pro, an integrated testing solution designed to give clinicians a faster and more comprehensive roadmap for treating patients with advanced solid tumors. The new offering combines multiple advanced testing modalities into a single, streamlined process, tackling the critical delays and uncertainties that often hinder the start of effective, personalized cancer therapy.

For patients with advanced cancer, time is the most precious commodity. Yet the very advancements that have created life-saving targeted therapies have also built a dauntingly complex diagnostic pathway. PanTracer Pro enters the market as a direct response to this growing challenge.

The Diagnostic Gauntlet: Navigating Cancer's Complex Reality

In the world of precision oncology, a tumor is no longer defined just by its location in the body but by its unique molecular signature. Identifying this signature requires a battery of tests to find specific biomarkers—gene mutations, fusions, and protein expressions—that can guide treatment. However, the process of uncovering this information is often slow and fragmented.

Clinicians frequently face what has become a diagnostic gauntlet. The traditional approach often involves sequential testing: ordering a test for one biomarker, waiting for the results, and then ordering another, and another. This piecemeal strategy consumes valuable time, with real-world turnaround for a complete molecular profile sometimes stretching to 24 days or more, far exceeding the 10-14 days recommended by clinical guidelines. These delays can lead to patient anxiety, disease progression, and force oncologists to start treatment with less effective, non-targeted chemotherapy while waiting for a complete picture.

Furthermore, this fragmented workflow is often hampered by a critical logistical challenge: insufficient tissue. Biopsies for advanced tumors can be small or difficult to obtain, and a single sample may not be large enough to endure the rigors of multiple, separate tests. When tissue runs out, the diagnostic process can grind to a halt, sometimes requiring a patient to undergo another invasive biopsy procedure.

A Unified Approach to Unlocking Tumor Biology

NeoGenomics designed PanTracer Pro to dismantle this inefficient system by integrating the most critical diagnostic tools into a single, coordinated order. The solution combines broad comprehensive genomic profiling (CGP), which uses DNA and RNA sequencing to scan over 500 cancer-related genes, with diagnosis-directed immunohistochemistry (IHC) and other ancillary tests selected based on the specific tumor type.

“Every delay or unanswered question in the diagnostic process can affect how quickly patients begin treatment,” said Tony Zook, chief executive officer at NeoGenomics, in the company’s announcement. “PanTracer Pro is designed to help clinicians get the information they need earlier and more reliably, so care teams can plan next steps with greater clarity and confidence across the care journey.”

By assessing a wide array of genomic biomarkers and protein expression levels upfront, the platform aims to deliver a holistic molecular profile within a competitive 8-to-10-day turnaround time. This speed is crucial for enabling timely, real-world treatment decisions.

Perhaps its most pragmatic feature is the built-in solution for tissue scarcity. If a submitted tissue sample is insufficient for a complete analysis, the test automatically reflexes to PanTracer LBx, the company's pan-solid tumor liquid biopsy assay. This seamless transition to a blood-based test allows the diagnostic workup to continue without interruption, preventing the need for a new order or a painful re-biopsy and ensuring that a comprehensive profile can still be obtained.

A Strategic Play in a Crowded Precision Medicine Field

The launch of PanTracer Pro is a calculated strategic move by NeoGenomics in the highly competitive oncology diagnostics market. The company is positioning itself against established players like Foundation Medicine (a Roche company), Guardant Health, and Caris Life Sciences, each with its own strengths in tissue- and liquid-based genomic profiling.

While competitors offer powerful tools, NeoGenomics' differentiation with PanTracer Pro appears to be a sharp focus on workflow integration. Instead of just offering a powerful test, the company is selling a more elegant and efficient process. Caris Life Sciences has championed a similar “multi-omic” approach by combining genomic and protein analysis, but NeoGenomics' single-order system, combined with the automatic liquid biopsy reflex, creates a compelling package designed to solve the day-to-day logistical headaches faced by pathology labs and oncology practices.

By bundling CGP, IHC, and a liquid biopsy backup into one product, NeoGenomics is betting that clinicians will value a solution that simplifies ordering, guarantees a comprehensive workup, and minimizes the risk of diagnostic dead ends. This strategy directly addresses the feedback from healthcare professionals who, while embracing the power of genomic medicine, are often burdened by the logistical complexity of its implementation.

Charting the Future of Personalized Cancer Care

PanTracer Pro is not just a new product but a reflection of the broader evolution of precision oncology. Leading clinical bodies like the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) increasingly recommend broad molecular profiling for all patients with advanced cancer. Integrated solutions that provide this level of detail efficiently are no longer a luxury but a necessity for practicing modern, guideline-directed medicine.

The market for such advanced tests continues to navigate a complex reimbursement landscape, where securing coverage from payers can be a significant hurdle. However, the undeniable clinical utility and growing support from medical guidelines are steadily pushing insurers toward broader coverage of comprehensive profiling.

Looking ahead, the future of cancer diagnostics lies in even greater integration, speed, and intelligence. The massive datasets generated by multi-omic platforms like PanTracer Pro are ripe for analysis by artificial intelligence (AI) and machine learning algorithms, which could uncover novel biomarkers and predict treatment responses with even greater accuracy. As liquid biopsy technology continues to mature, its role will expand from a backup plan to a primary tool for everything from initial diagnosis to monitoring treatment response and detecting disease recurrence.

By launching PanTracer Pro, NeoGenomics is making a clear statement that the future of cancer diagnostics is not just about generating more data, but about delivering that data in a smarter, faster, and more integrated way to make a meaningful difference at the patient's bedside.